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Angiogenesis, the development of new blood vessels, is an essen-
tial requirement for both primary and metastatic tumour growth. In
the absence of angiogenesis tumours cannot grow beyond 1–
2m m 3 in size (Gimbrone et al, 1972). The ability of tumours to
stimulate neovascularization is governed by the net balance of
angiogenic stimulators and inhibitors (Hanahan and Folkman,
1996). Tumours can secrete or mobilize a variety of angiogenic
factors that tip the balance in favour of angiogenesis. Vascular
endothelial growth factor (VEGF) also known as vascular perme-
ability factor, VPF, is a potent angiogenic factor and endothelial
cell mitogen (Jakeman et al, 1992). Produced by a variety of cell
types and tumours, its major action has been attributed to the
neovascularization of tumours. By increasing vascular perme-
ability (Senger et al, 1983), resulting in the leaky vasculature
characteristic of tumour angiogenesis, VEGF facilitates extra-
vasation of tumour cells and the new vessels induced by VEGF
provide an exit route for metastatic tumour cells. 
Under normal physiological conditions, a delicate balance
between cell proliferation and cell death ensures that the overall
numbers of cells are maintained within an appropriate range. The
selective process whereby cells are discretely removed from popu-
lations without affecting surrounding cells is termed apoptosis or
‘programmed cell death’. Disturbances in this process may confer
a growth advantage to neoplastic tissues (Thompson, 1995). The
Bcl-2 family of apoptosis-regulating proteins function to either
promote or suppress cell death (Oltvai et al, 1993). Increased
expression of the anti-apoptotic protein, Bcl-2, has been reported
in many tumours and paradoxically, increased expression of 
Bcl-2 is a good prognostic indicator in some cancers (Krawjewski
et al, 1999). Conversely, overexpression of Bcl-XL reduced
chemotherapy-induced apoptosis of mammary tumours in a
murine model (Liu et al, 1999). 
VEGF has been shown to protect endothelial cells from apop-
tosis induced by growth factor withdrawal, and this protection is
associated with increased Bcl-2 expression (Nor et al, 1999).
Furthermore, VEGF has been shown to protect non-endothelial
cells, namely leukaemia cells and haematopoietic stem cells, from
radiation-induced apoptosis (Katoh et al, 1998) whereas neutral-
izing antibody to VEGF increased the efficacy of ionizing radia-
tion in tumour-bearing mice (Gorski et al, 1999). 
Endotoxin/lipopolysaccharide (LPS), a cell wall constituent of
Gram-negative bacteria, is released during growth or lysis of
bacteria and acts as a potent inflammatory stimulus, eliciting a
range of cytokines. In an experimental metastasis model we previ-
ously demonstrated that intra-peritoneal injection of LPS resulted
in elevated circulating VEGF and decreased apoptosis within lung
metastases relative to control mice (Pidgeon et al, 1999). In vitro,
LPS directly increased VEGF expression by 4T1 murine mam-
mary adenocarcinoma cells and increased VEGF expression 
by human pulp cells exposed to LPS has also been reported
(Matsushita et al, 1999; Pidgeon et al, 1999). 
We hypothesized that VEGF acts as a survival factor for tumour
cells as well as endothelial cells, inhibiting tumour cell apoptosis
by inducing Bcl-2 expression. Bcl-2 expression and apoptosis in
human MDA-MB-231 and murine 4T1 cells in response to VEGF,
LPS (to stimulate VEGF) and neutalizing antibodies to VEGF (to
block endogenous or exogenous VEGF) were evaluated. 
MATERIALS AND METHODS 
Cell culture 
The spontaneously metastasizing murine mammary adenocarci-
noma cell line 4T1 was generously provided by Mr E Coveny
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mammary metastatic cell line MDA-MB-231 was originally
obtained from the ATCC. All cell culture reagents were obtained
from GIBCO-BRL (Paisley, UK). The 4T1 cells were maintained in
a humidified atmosphere of 5% CO2 in air at 37°C in RPMI, supple-
mented with 10% heat-inactivated fetal calf serum, 100 U ml–1 peni-
cillin and 100 mg ml–1 streptomycin sulfate. The MDA-MB-231
cells were maintained in sealed flasks at 37°C in L-15, supple-
mented with 10% heat-inactivated fetal calf serum, 100 U ml–1 peni-
cillin and 100 mg ml–1 streptomycin sulfate. In-vitro experiments
were performed when cells were approximately 80% confluent.
Treatment of cells 
For Western analysis, cells were seeded at 5 ´ 105 cells/75 cm3
flask. Cells were allowed to recover for 18–24 h and then incu-
bated with either 10 mg ml–1 LPS (to induce VEGF expression),
100 ng ml–1 recombinant VEGF (R&D Systems, UK), 10 mg ml–1
LPS with 1 mg ml–1 neutralizing VEGF pAb (R&D Systems, UK)
or VEGF pAb alone for 18 h. 
Western analysis 
Culture fluid was aspirated and cells pelleted at 300 g for 10 min
and combined with adherent cells which were washed twice with
PBS and lysed on ice for 30 min in 1 ml lysis buffer (5 mM Tris-
HCL, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5 % Triton X-100,
0.5 % SDS. 0.005% deoxycholate) 1 mM phenylmethylsul-
fonylflouride (PMSF). Lysates were passed through a 20 G needle,
boiled for 10 min and centrifuged at 12 000 g for 15 min at 4°C.
Total protein concentration in cleared lysate was determined by
the BCA assay according to manufacturers instructions (Pierce
Chemical Co, Illinois). 50 mg protein was separated on 12%
denaturing polyacrylamide gels and transferred to nitrocellulose
membranes by electroblotting. Membranes were blocked for 1
hour with Tris-buffered saline containing 0.05% Tween 20 (TBST)
and 5% non-fat milk protein and incubated for 90 min with anti-
Bcl-2 or anti-b-actin antibodies diluted 1:200 in TBST containing
5% non-fat dried milk (Santa Cruz Biotech, CA, US). The
membrane was washed 3 times in TBST, incubated for 90 min
with horse-radish peroxidase conjugated goat anti-rabbit IgG
(1:2000 in TBST, Dako), and washed 6 times in TBST. Bound
antibody complexes were visualized using enhanced chemilumi-
nescence (Pierce Chemical Co, IL). 
Antibody binding was quantitated densitometrically (Vilber-
Lourmat, Marne La Vallee, France). The amount of Bcl-2 staining
was normalized against b-actin staining by calculating a bcl-2/b-
action ratio for each sample. 
TUNEL staining for apoptosis 
Cells were seeded on glass (MDA-MB-231) or plastic (4T1)
culture chamber slides (Falcon, UK) at a concentration of 5 ´ 104
cells/chamber, allowed to recover overnight and then treated for
18 h with the same treatment protocol outlined previously. Culture
medium was supplemented with 1% FCS (as opposed to 10%) to
stimulate apoptosis by growth factor withdrawal. Culture chamber
slides were fixed in 100% acetone for 5 min and apoptotic cells
were stained using the in situ cell death detection assay
(Boehringer Mannheim, UK) for the demonstration of DNA frag-
mentation. Sections were counterstained with haematoxylin.
Apoptotic cells stained brown and an apoptotic index was esti-
mated under a light microscope at ´ 400 magnification using a 
1 mm grid by 2 independent observers (GP and MB). A minimum
of 3000 cells (6 high-power fields) were counted over 3 separate
chambers of each treatment group. 
Statistical analysis 
Statistical comparison between study groups was carried out using
ANOVA with Scheffe post-hoc correction in DataDesk 4.1.
Results are expressed as mean ± standard error mean (SEM). Data
were taken as significant where P < 0.05. 
RESULTS 
We previously examined the effect of LPS exposure on tumour
growth in a murine model where experimental lung metastases
were established by tail vein injection of 4T1 tumour cells. LPS
exposure resulted in increased circulating VEGF and decreased
apoptosis within lung tumour nodules (Pidgeon et al, 1999). In this
study we examined the effect of VEGF on tumour cell apoptosis
using LPS to induce VEGF expression and a neutralizing antibody
to block VEGF activity. We previously showed that 10 mg ml–1
LPS for 18 h increased VEGF expression by 4T1 cells from a
basal level of 59.1 ± 1.87 to 117.22 ± 11.89 pg VEGF mg–1 total
cell protein (P < 0.01) (Pidgeon et al, 1999). Basal VEGF expres-
sion by MDA-MB-231 cells was less than 4T1 cells but was also
significantly increased following treatment with 10 mg ml–1 LPS
for 18 h (from 20.56 ± 1.51 to 28.32 ± 2.05 pg VEGF mg–1 total
cell protein (P < 0.05)). 
Effect of VEGF, LPS and anti-VEGF antibodies on Bcl-2
protein expression 
The level of Bcl-2 protein expression was examined by Western
blot analysis following treatment with LPS, VEGF and/or anti-
VEGF antibodies. The neutralization dose50, that is the dose of
antibody required to yield one half maximal inhibition, (ND50) for
anti-hVEGF was 5–10 mg ml–1 to neutralize 10 ng ml–1 rhVEGF
and for anti-mVEGF the ND50 was 0.05–0.15 mg ml–1 to neutralize
10 ng ml–1 rmVEGF. Western blot analysis showed that VEGF
(100 ng ml–1) or LPS (10 mg ml–1) resulted in increased Bcl-2
expression in both 4T1 and MDA-MB-231 cells relative to
controls (Figure 1A and Figure 2A, respectively). Densitometry
confirmed that relative Bcl-2 expression by 4T1 and MDA-MB-
231 cells was significantly increased following treatment with
either LPS (4T1, 140 ± 7.5%; MDA-MB-231, 138 ± 13.4%) or
VEGF (4T1, 136 ± 7.6%; MDA-MB-231, 166 ± 31.2%) compared
to controls (P < 0.02, Figure 1B and Figure 2B, respectively). The
addition of a neutralizing anti-VEGF antibody (1 mgm l –1)
decreased Bcl-2 protein expression in both cell lines (4T1, 46 ±
10.2%; MDA-MB-231, 18 ± 3.5%). In this case the antibody is
blocking basal VEGF expressed by the tumour cells.
Densitometric analysis illustrated that this blockade of endoge-
nous VEGF was significant relative to controls (P < 0.03). Anti-
VEGF antibodies blocked LPS induced Bcl-2 expression resulting
in a significant decrease in Bcl-2 protein levels relative to controls
(4T1, 51 ± 11.1%; MDA-MB-231, 48 ± 6.6%) (P < 0.03).
However, in the case of MDA-MB-231 cells, in the presence of
LPS, VEGF antibody did not inhibit Bcl-2 expression as much as
VEGF antibody alone. LPS is a non-specific stimulus and may
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These data show that anti-VEGF antibodies reduce Bcl-2 expres-
sion in both 4T1 and MDA-MB-231 cells. Furthermore both LPS
and VEGF treatment increase Bcl-2 expression and anti-VEGF
blocks LPS-induced Bcl-2 expression. 
Effect of VEGF, LPS and anti-VEGF antibodies on
tumour cell apoptosis 
Having demonstrated that LPS and VEGF upregulate expression
of the anti-apoptotic protein, Bcl-2, in human and murine tumour
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Figure 1 (A) Bcl-2 protein expression in 4T1 cells. Bcl-2 expression was
examined by Western blot. b-actin expression was also examined to control
for loading differences. Untreated cells are shown in lane 1. Treatment with
10 mg ml–1 LPS (lane 2) or 100 ng ml–1 VEGF (lane 5) resulted in increased
Bcl-2 expression relative to control cells. Neutralizing antibody to VEGF alone
reduced basal Bcl-2 expression relative to controls (lane 4) and blocked LPS-
induced Bcl-2 (lane 3). Western blot shown is representative of 4 independent
experiments. (B) Densitometric analysis of Bcl-2 protein relative to b-actin.
Values are expressed as expression relative to control cells (100%) 
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Figure 2 (A) Bcl-2 protein expression in MDA-MB-231 cells. Bcl-2
expression was examined by Western blot. b-actin expression was also
examined to control for loading differences. Untreated cells are shown in 
lane 1. Treatment with 10 mg ml–1 LPS (lane 2) or 100 ng ml–1 VEGF (lane 5)
resulted in increased Bcl-2 expression relative to control cells. Neutralizing
antibody to VEGF alone reduced basal Bcl2 expression relative to controls
(lane 4) and blocked LPS-induced Bcl-2 (lane 3). Western blot shown is
representative of 3 independent experiments. (B) Densitometric analysis of
Bcl-2 protein relative to b-actin. Values are expressed as expression relative
to control cells (100%) 
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Figure 3 (A) Levels of apoptosis in 4T1 cells were examined in chamber slides by TUNEL staining (n = 3). Apoptosis was induced to a level of 10.04% in control
cells by growth factor depletion. Treatment with 10 mg ml–1 LPS or 100 ng ml–1 VEGF resulted in a significant reduction in the percentage of cells undergoing
apoptosis. Antibody to VEGF alone significantly increased apoptosis relative to controls (P < 0.03) and inhibited LPS-mediated inhibition of apoptosis. *P < 0.05 vs
control; # P < 0.05 vs LPS. (B) Levels of apoptosis in MDA-MB-231 cells were examined (n = 3). Apoptosis was induced to a level of 8.4% in control cells by growth
factor depletion. Treatment with 10 mg ml–1 LPS or 100 ng ml–1 VEGF resulted in a significant reduction in the percentage of cells undergoing apoptosis. Antibody to
VEGF alone significantly increased apoptosis relative to controls (P < 0.03) and inhibited LPS-mediated inhibition of apoptosis. *P < 0.05 vs control; # P < 0.05 vs
LPS. (C) Representative MDA-MB-231 cells from each treatment group following TUNEL staining. Bar represents 100 mm 
C. CONTROL +LPS
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+VEGFcells and that this expression can be blocked with anti-VEGF anti-
bodies, we studied their effect on tumour cell apoptosis directly by
TUNEL staining on culture chamber slides. Due to the low basal
rate of apoptosis in tumour cells, apoptosis was induced to a level
of 10.33 ± 1.41% in 4T1 and 8.4 ± 0.47% in MDA-MB-231 cells
by growth factor withdrawal (Figure 3A and B, respectively).
Treatment with LPS (4T1, 5.39 ± 0.66%; MDA-MB-231, 3.4 ±
0.18%) or VEGF (4T1, 4.07 ± 0.44%; MDA-MB-231, 4.2 ±
0.39%) resulted in a significant decrease in the rate of apoptosis
compared to untreated cells (4T1, 10.33 ± 1.41%; MDA-MB-231,
8.4 ± 0.47% P < 0.05, Figure 3A and B, respectively). Treatment
of cells with anti-VEGF antibodies resulted in a significant
increase in the level of apoptosis in both cell lines (24.2 ± 0.90%,
P < 0.01 in 4T1 cells and 22 ± 2.84%, P < 0.02 in MDA-MB-231
cells). In both cell lines, anti-VEGF antibodies prevented LPS-
mediated inhibition of apoptosis compared to cells treated with
LPS alone (15.12 ± 1.98% vs 5.39 ± 0.66%, P < 0.01 in 4T1) and
(11.8 ± 2.23% vs 3.4 ± 0.18%, P < 0.005 in MDA-MB-231).
Typical stained MDA-MB-231 cells from each treatment group are
shown in Figure 3C. Increased numbers of TUNEL-positive cells
are clearly visible in samples treated with anti-VEGF antibody
relative to untreated controls. Blocking either endogenous VEGF
produced by tumour cells or exogenous VEGF (in this case
induced by LPS exposure) leads to increased apoptosis, indicating
that VEGF increases tumour cell survival by inhibiting apoptosis. 
DISCUSSION 
The potent inflammatory mediator endotoxin/lipopolysaccharide
(LPS) has been shown to be angiogenic in a number of experi-
mental systems (Li et al, 1991; Mattsby-Balzer et al, 1994;
Kenyon et al, 1996). However, the mechanism of its angiogenic
activity has to date, been unknown. We previously demonstrated
that LPS increases VEGF expression by human and murine
metastatic breast carcinoma cells (Pidgeon et al, 1999). As LPS
also increased VEGF expression by pulp cells (Matsushita et al,
1999), increased VEGF expression may account for the angio-
genic activity of LPS previously reported. 
VEGF has previously been shown to induce the expression of
the anti-apoptotic protein Bcl-2 in endothelial cells, thereby
prolonging their survival (Nor et al, 1999). We have demonstrated
that both endogenous and exogenous VEGF (rVEGF) increased
Bcl-2 expression with a concomitant inhibition of apoptosis in
murine and human metastatic tumour cells. Neutralizing antibody
to VEGF, reduced Bcl-2 expression and increased apoptosis in
these cells. LPS induced Bcl-2 expression and inhibition of tumour
cell apoptosis was abolished by anti-VEGF antibodies, demon-
strating that these effects of LPS were mediated by VEGF. 
Typically VEGF has been considered an endothelial cell
specific survival factor. However, we demonstrate that VEGF is a
survival factor for both murine 4T1 and human MDA-MB-231
tumour cells, preventing tumour cell apoptosis. The signalling
pathway through which VEGF acts on tumour cells remains to be
clarified. However, recently a novel third receptor, neuropilin 1,
specific for VEGF165, has been identified on a number of tumour
cells including MDA-MB-231 (Soker et al, 1998). Western blot
analysis has failed to identify either KDR/Flk-1 or Flt1, the VEGF
receptors expressed by endothelial cells, in 4T1 or MDA-MB-231
cells (data not shown). A role for VEGF in preventing tumour cell
apoptosis is further supported by recent reports that overexpres-
sion of soluble neuropilin 1(sNRP1), which prevents VEGF165
binding to cell surface receptors, in tumour cells was associated
with increased tumour cell apoptosis in vitro (Gagnon et al, 2000).
These authors also demonstrated that sNRP1 prevented VEGF165
binding to rat prostate carcinoma cells, although the consequences
of VEGF binding to these tumour cells was unknown. VEGF has
been shown to upregulate the expression of the KDR receptor on
endothelial cells which may be a positive feedback mechanism for
VEGF action (Shen et al, 1998). Thus strategies that block VEGF
activity may reduce VEGF receptor expression. Decreased VEGF
receptor expression may therefore lead to an overall reduction in
VEGF expression. 
Anti-angiogenic therapy has received a lot of attention in the
last decade. A number of studies have shown that anti-angiogenic
strategies result in increased tumour cell apoptosis (Holmgren 
et al, 1995) an effect that to date, has been attributed to blood
vessel regression. However, the angiogenic factor VEGF inhibits
radiation-induced tumour cell apoptosis and chemotherapy-
induced apoptosis of haematopoietic cells, the latter effect being
achieved by the induction of MCL1, a member of the bcl-2 family
(Katoh et al, 1998; Gorski et al, 1999). These observations can be
explained in terms of our findings, namely that VEGF acts directly
on tumour cells to prevent apoptosis. Our study suggests that anti-
angiogenics, in particular those directed against VEGF, may have
multiple anti-tumour effects. Firstly, they prevent endothelial cell
growth inducing apoptosis resulting in regression of tumour
vessels. Secondly, by blocking or reducing angiogenic molecules
they may have a direct anti-tumour effect by increasing tumour
cell apoptosis. 
In conclusion, we have demonstrated that VEGF confers a
survival advantage on tumour cells by upregulating Bcl-2 expres-
sion and inhibition of tumour cell apoptosis. Furthermore, neutral-
izing antibody to VEGF increased the efficacy of ionizing
radiation in tumour-bearing mice (Gorski et al, 1999). Thus 
anti-VEGF strategies, as part of combination therapy, should
improve the efficacy of conventional treatments aimed at inducing
tumour cell apoptosis, such as chemotherapy and/or radiation
therapy. 
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